<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">35469345</PMID><DateCompleted><Year>2022</Year><Month>04</Month><Day>27</Day></DateCompleted><DateRevised><Year>2022</Year><Month>07</Month><Day>16</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2314-7156</ISSN><JournalIssue CitedMedium="Internet"><Volume>2022</Volume><PubDate><Year>2022</Year></PubDate></JournalIssue><Title>Journal of immunology research</Title><ISOAbbreviation>J Immunol Res</ISOAbbreviation></Journal><ArticleTitle>Association of HLA-DR1, HLA-DR13, and HLA-DR16 Polymorphisms with Systemic Lupus Erythematosus: A Meta-Analysis.</ArticleTitle><Pagination><StartPage>8140982</StartPage><MedlinePgn>8140982</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">8140982</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1155/2022/8140982</ELocationID><Abstract><AbstractText Label="OBJECTIVES" NlmCategory="UNASSIGNED">The principal purpose of this meta-analysis was to assess the association between HLA-DRB1 (HLA-DR1, HLA-DR13, and HLA-DR16) polymorphisms and SLE susceptibility.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We searched published case-control studies on the association between HLA-DRB1 polymorphisms and SLE susceptibility from PubMed and Web of Science databases. The pooled ORs with 95% CIs were utilized to estimate the strength of association of HLA-DR1, HLA-DR13, and HLA-DR16 polymorphisms and SLE susceptibility by fixed effect models. We also performed sensitivity analysis, trial sequential analysis, Begg's test, and Egg's test in this meta-analysis.</AbstractText><AbstractText Label="RESULTS" NlmCategory="UNASSIGNED">A total of 18 studies were included in this meta-analysis. Overall analysis showed that HLA-DR1 and HLA-DR13 polymorphisms were associated with a decreased risk of SLE (OR = 0.76, 95% CI: 0.65-0.90, <i>P</i> &lt; 0.01; OR = 0.58, 95% CI: 0.50-0.68, <i>P</i> &lt; 0.01), and HLA-DR16 polymorphism was associated with an increased risk of SLE (OR = 1.70, 95% CI: 1.24-2.33, <i>P</i> &lt; 0.01). In subgroup analysis of ethnicity, the results were as follows: HLA-DR1 polymorphism in Caucasians (OR = 0.76, 95% CI: 0.58-0.98,<i>P</i> = 0.04) and North Americans (OR = 0.64, 95% CI: 0.42-0.96,<i>P</i> = 0.03); HLA-DR13 polymorphism in Caucasians (OR = 0.62, 95% CI: 0.47-0.82,<i>P</i> &lt; 0.01) and East Asians (OR = 0.44, 95% CI: 0.34-0.57,<i>P</i> &lt; 0.01); and HLA-DR16 polymorphism in East Asians (OR = 2.62, 95% CI: 1.71-4.03,<i>P</i> &lt; 0.01).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="UNASSIGNED">This meta-analysis showed that HLA-DR1 and HLA-DR13 are protective factors for SLE, and HLA-DR16 is a risk factor. Due to the limitations of this meta-analysis, the association between HLA-DRB1 polymorphisms and SLE susceptibility needs to be further researched before definitive conclusions are proved.</AbstractText><CopyrightInformation>Copyright &#xa9; 2022 Tingrui Wang et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Tingrui</ForeName><Initials>T</Initials><Identifier Source="ORCID">0000-0002-0488-4304</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hong</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Qiu</LastName><ForeName>Lijuan</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Lingling</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ling</LastName><ForeName>Huayun</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xue</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhou</LastName><ForeName>Ying</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chen</LastName><ForeName>Huijuan</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ye</LastName><ForeName>Dong-Qing</ForeName><Initials>DQ</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Bin</ForeName><Initials>B</Initials><Identifier Source="ORCID">0000-0001-6371-210X</Identifier><AffiliationInfo><Affiliation>Department of Epidemiology and Biostatistics, School of Public Health, Anhui Medical University, Hefei, Anhui, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Inflammation and Immune Mediated Diseases Laboratory of Anhui Province, Hefei, Anhui, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D017418">Meta-Analysis</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>04</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>Egypt</Country><MedlineTA>J Immunol Res</MedlineTA><NlmUniqueID>101627166</NlmUniqueID><ISSNLinking>2314-7156</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059810">HLA-DR Serological Subtypes</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015798">HLA-DR1 Antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C097337">HLA-DR13 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C067266">HLA-DR16 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059811">HLA-DRB1 Chains</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D020022" MajorTopicYN="N">Genetic Predisposition to Disease</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059810" MajorTopicYN="N">HLA-DR Serological Subtypes</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015798" MajorTopicYN="Y">HLA-DR1 Antigen</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059811" MajorTopicYN="N">HLA-DRB1 Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008180" MajorTopicYN="Y">Lupus Erythematosus, Systemic</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020641" MajorTopicYN="N">Polymorphism, Single Nucleotide</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>26</Day><Hour>5</Hour><Minute>37</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>27</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>4</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35469345</ArticleId><ArticleId IdType="pmc">PMC9034954</ArticleId><ArticleId IdType="doi">10.1155/2022/8140982</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fortuna G., Brennan M. T. Systemic lupus erythematosus: epidemiology, pathophysiology, manifestations, and management. Dental Clinics of North America . 2013;57(4):631&#x2013;655. doi: 10.1016/j.cden.2013.06.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cden.2013.06.003</ArticleId><ArticleId IdType="pubmed">24034070</ArticleId></ArticleIdList></Reference><Reference><Citation>Durcan L., O&#x2019;Dwyer T., Petri M. Management strategies and future directions for systemic lupus erythematosus in adults. Lancet . 2019;393(10188):2332&#x2013;2343. doi: 10.1016/S0140-6736(19)30237-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(19)30237-5</ArticleId><ArticleId IdType="pubmed">31180030</ArticleId></ArticleIdList></Reference><Reference><Citation>Graham R. R., Ortmann W. A., Langefeld C. D., et al. Visualizing human leukocyte antigen class II risk haplotypes in human systemic lupus erythematosus. American Journal of Human Genetics . 2002;71(3):543&#x2013;553. doi: 10.1086/342290.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/342290</ArticleId><ArticleId IdType="pmc">PMC379191</ArticleId><ArticleId IdType="pubmed">12145745</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter E. E., Barr S. G., Clarke A. E. The global burden of SLE: prevalence, health disparities and socioeconomic impact. Nature Reviews Rheumatology . 2016;12(10):605&#x2013;620. doi: 10.1038/nrrheum.2016.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrrheum.2016.137</ArticleId><ArticleId IdType="pubmed">27558659</ArticleId></ArticleIdList></Reference><Reference><Citation>Beccastrini E., D'Elios M. M., Emmi G., et al. Systemic lupus erythematosus: immunopathogenesis and novel therapeutic targets. International Journal of Immunopathology and Pharmacology . 2013;26(3):585&#x2013;596. doi: 10.1177/039463201302600302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/039463201302600302</ArticleId><ArticleId IdType="pubmed">24067455</ArticleId></ArticleIdList></Reference><Reference><Citation>Kronbichler A., Mayer G. Renal involvement in autoimmune connective tissue diseases. BMC Medicine . 2013;11:p. 95. doi: 10.1186/1741-7015-11-95.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1741-7015-11-95</ArticleId><ArticleId IdType="pmc">PMC3616816</ArticleId><ArticleId IdType="pubmed">23557013</ArticleId></ArticleIdList></Reference><Reference><Citation>Bodis G., Toth V., Schwarting A. Role of human leukocyte antigens (HLA) in autoimmune diseases. Methods in Molecular Biology . 2018;1802:11&#x2013;29. doi: 10.1007/978-1-.4939-8546-3_2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-1-.4939-8546-3_2</ArticleId><ArticleId IdType="pubmed">29858799</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong M., Tsao B. P. Current topics in human SLE genetics. Springer Seminars in Immunopathology . 2006;28(2):97&#x2013;107. doi: 10.1007/s00281-006-0031-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-006-0031-6</ArticleId><ArticleId IdType="pubmed">16941108</ArticleId></ArticleIdList></Reference><Reference><Citation>Kishore A., Petrek M. Next-generation sequencing based HLA typing: deciphering immunogenetic aspects of sarcoidosis. Frontiers in Genetics . 2018;9:p. 503. doi: 10.3389/fgene.2018.00503.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2018.00503</ArticleId><ArticleId IdType="pmc">PMC6210504</ArticleId><ArticleId IdType="pubmed">30410504</ArticleId></ArticleIdList></Reference><Reference><Citation>Klein J., Sato A. The HLA system. First of two parts. The New England Journal of Medicine . 2000;343(10):702&#x2013;709. doi: 10.1056/NEJM200009073431006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM200009073431006</ArticleId><ArticleId IdType="pubmed">10974135</ArticleId></ArticleIdList></Reference><Reference><Citation>Cruz-Tapias P., P&#xe9;rez-Fern&#xe1;ndez O. M., Rojas-Villarraga A., Rodr&#xed;guez-Rodr&#xed;guez A., Arango M. T., Anaya J. M. Shared HLA Class II in Six Autoimmune Diseases in Latin America: A Meta-Analysis. Autoimmune Diseases . 2012;2012:10. doi: 10.1155/2012/569728.569728</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/569728</ArticleId><ArticleId IdType="pmc">PMC3345213</ArticleId><ArticleId IdType="pubmed">22577522</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando M. M., Stevens C. R., Sabeti P. C., et al. Identification of two independent risk factors for lupus within the MHC in United Kingdom families. PLoS Genetics . 2007;3(11, article e192) doi: 10.1371/journal.pgen.0030192.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.0030192</ArticleId><ArticleId IdType="pmc">PMC2065882</ArticleId><ArticleId IdType="pubmed">17997607</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue K., Niu W. Q., Cui Y. Association of HLA-DR3 and HLA-DR15 polymorphisms with risk of systemic lupus erythematosus. Chinese Medical Journal . 2018;131(23):2844&#x2013;2851. doi: 10.4103/0366-6999.246058.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/0366-6999.246058</ArticleId><ArticleId IdType="pmc">PMC6278195</ArticleId><ArticleId IdType="pubmed">30511687</ArticleId></ArticleIdList></Reference><Reference><Citation>Niu Z., Zhang P., Tong Y. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. International Journal of Rheumatic Diseases . 2015;18(1):17&#x2013;28. doi: 10.1111/1756-185X.12528.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/1756-185X.12528</ArticleId><ArticleId IdType="pubmed">25546242</ArticleId></ArticleIdList></Reference><Reference><Citation>Fojt&#xed;kov&#xe1; M., Novota P., &#x10c;ejkov&#xe1; P., Pe&#x161;i&#x10d;kov&#xe1; S., Tegzov&#xe1; D., &#x10c;ern&#xe1; M. HLA class II, MICA and PRL gene polymorphisms: the common contribution to the systemic lupus erythematosus development in Czech population. Rheumatology International . 2011;31(9):1195&#x2013;1201. doi: 10.1007/s00296-010-1431-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-010-1431-4</ArticleId><ArticleId IdType="pubmed">20352225</ArticleId></ArticleIdList></Reference><Reference><Citation>Furukawa H., Kawasaki A., Oka S., et al. Human leukocyte antigens and systemic lupus erythematosus: a protective role for the HLA-DR6 alleles DRB1&#x2217;13&#x2009;: 02 and &#x2217;14: 03. PLoS One . 2014;9(2, article e87792) doi: 10.1371/journal.pone.0087792.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0087792</ArticleId><ArticleId IdType="pmc">PMC3912000</ArticleId><ArticleId IdType="pubmed">24498373</ArticleId></ArticleIdList></Reference><Reference><Citation>Garcia-Silva R., Hernandez-Do&#xf1;o S., Rom&#xe1;n-Amparo J. P., et al. Mayan alleles of the HLA-DRB1 major histocompatibility complex might contribute to the genetic susceptibility to systemic lupus erythematosus in Mexican patients from Tapachula, Chiapas. Clinical Rheumatology . 2021;40(8):3095&#x2013;3103. doi: 10.1007/s10067-021-05636-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-021-05636-4</ArticleId><ArticleId IdType="pubmed">33575923</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstein R., Sengar D. P. Comparative studies of the major histocompatibility complex in French Canadian and non-French Canadian Caucasians with systemic lupus erythematosus. Arthritis and Rheumatism . 1993;36(8):1121&#x2013;1127. doi: 10.1002/art.1780360813.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780360813</ArticleId><ArticleId IdType="pubmed">8343187</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachicha H., Kammoun A., Mahfoudh N., et al. Human leukocyte antigens-DRB1&#x2217;03 is associated with systemic lupus erythematosus and anti-SSB production in South Tunisia. International Journal of Health Sciences . 2018;12(1):21&#x2013;27.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5870315</ArticleId><ArticleId IdType="pubmed">29623013</ArticleId></ArticleIdList></Reference><Reference><Citation>Hrycek A., Siekiera U., Cie&#x15b;lik P., Szkr&#xf3;bka W. HLA-DRB1 and -DQB1 alleles and gene polymorphisms of selected cytokines in systemic lupus erythematosus. Rheumatology International . 2005;26(1):1&#x2013;6. doi: 10.1007/s00296-004-0503-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00296-004-0503-8</ArticleId><ArticleId IdType="pubmed">15449022</ArticleId></ArticleIdList></Reference><Reference><Citation>Katkam S. K., Rajasekhar L., Kutala V. K. The influence of functional polymorphic positions of HLA-DR&#x3b2;1 molecules on risk for South Indian systemic lupus erythematosus patients. Lupus . 2018;27(6):991&#x2013;1000. doi: 10.1177/0961203318759200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203318759200</ArticleId><ArticleId IdType="pubmed">29439646</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim T. G., Kim H. Y., Lee S. H., et al. Systemic lupus erythematosus with nephritis is strongly associated with the TNFB&#x2217;2 homozygote in the Korean population. Human Immunology . 1996;46(1):10&#x2013;17. doi: 10.1016/0198-8859(95)00170-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0198-8859(95)00170-0</ArticleId><ArticleId IdType="pubmed">9157084</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L. Y., Ding W. Z., Fici D., et al. Molecular analysis of major histocompatibility complex allelic associations with systemic lupus erythematosus in Taiwan. Arthritis and Rheumatism . 1997;40(6):1138&#x2013;1145. doi: 10.1002/art.1780400619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/art.1780400619</ArticleId><ArticleId IdType="pubmed">9182925</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohd-Yusuf Y., Phipps M. E., Chow S. K., Yeap S. S. HLA-A&#x2217;11 and novel associations in Malays and Chinese with systemic lupus erythematosus. Immunology Letters . 2011;139(1-2):68&#x2013;72. doi: 10.1016/j.imlet.2011.05.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2011.05.001</ArticleId><ArticleId IdType="pubmed">21658414</ArticleId></ArticleIdList></Reference><Reference><Citation>Naves M., Hajeer A. H., Teh L. S., et al. Complement C4B null allele status confers risk for systemic lupus erythematosus in a Spanish population. European Journal of Immunogenetics . 1998;25(4):317&#x2013;320. doi: 10.1046/j.1365-2370.1998.00110.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2370.1998.00110.x</ArticleId><ArticleId IdType="pubmed">9777334</ArticleId></ArticleIdList></Reference><Reference><Citation>Reveille J. D., Moulds J. M., Ahn C., et al. Systemic lupus erythematosus in three ethnic groups: I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. Arthritis and Rheumatism . 1998;41(7):1161&#x2013;1172. doi: 10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(199807)41:7&lt;1161::AID-ART4&gt;3.0.CO;2-K</ArticleId><ArticleId IdType="pubmed">9663471</ArticleId></ArticleIdList></Reference><Reference><Citation>Rood M. J., van Krugten M. V., Zanelli E., et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis and Rheumatism . 2000;43(1):129&#x2013;134. doi: 10.1002/1529-0131(200001)43:1&lt;129::AID-ANR16&gt;3.0.CO;2-S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1529-0131(200001)43:1&lt;129::AID-ANR16&gt;3.0.CO;2-S</ArticleId><ArticleId IdType="pubmed">10643708</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraja M., Chin V. K., Abdullah M., Arip M., Amin-Nordin S. HLA-DRB1&#x2217;04 as a risk allele to systemic lupus erythematosus and lupus nephritis in the Malay population of Malaysia. Frontiers in medicine . 2021;7, article 598665 doi: 10.3389/fmed.2020.598665.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2020.598665</ArticleId><ArticleId IdType="pmc">PMC7902771</ArticleId><ArticleId IdType="pubmed">33644084</ArticleId></ArticleIdList></Reference><Reference><Citation>Vasconcelos C., Carvalho C., Leal B., et al. HLA in Portuguese systemic lupus erythematosus patients and their relation to clinical features. Annals of the New York Academy of Sciences . 2009;1173(1):575&#x2013;580. doi: 10.1111/j.1749-6632.2009.04873.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.2009.04873.x</ArticleId><ArticleId IdType="pubmed">19758202</ArticleId></ArticleIdList></Reference><Reference><Citation>Wadi W., Elhefny N. E., Mahgoub E. H., et al. Relation between HLA typing and clinical presentations in systemic lupus erythematosus patients in Al-Qassim region, Saudi Arabia. International Journal of Health Sciences . 2014;8(2):159&#x2013;165. doi: 10.12816/0006082.</Citation><ArticleIdList><ArticleId IdType="doi">10.12816/0006082</ArticleId><ArticleId IdType="pmc">PMC4166988</ArticleId><ArticleId IdType="pubmed">25246883</ArticleId></ArticleIdList></Reference><Reference><Citation>Yao Z., Kimura A., Hartung K., et al. Polymorphism of the DQA1 promoter region (QAP) and DRB1, QAP, DQA1, DQB1 haplotypes in systemic lupus erythematosus. Immunogenetics . 1993;38(6):421&#x2013;429. doi: 10.1007/BF00184522.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00184522</ArticleId><ArticleId IdType="pubmed">8406614</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J. B., Ai R., Chow F. Serum levels of interleukin-1 beta, interleukin-6 and melatonin over summer and winter in kidney deficiency syndrome in Bizheng rats. Chinese Medical Sciences Journal . 2014;12(2):107&#x2013;110. doi: 10.1016/S1001-9294(14)60037-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1001-9294(14)60037-7</ArticleId><ArticleId IdType="pubmed">24998233</ArticleId></ArticleIdList></Reference><Reference><Citation>Weckerle C. E., Niewold T. B. The unexplained female predominance of systemic lupus erythematosus: clues from genetic and cytokine studies. Clinical Reviews in Allergy and Immunology . 2011;40(1):42&#x2013;49. doi: 10.1007/s12016-009-8192-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12016-009-8192-4</ArticleId><ArticleId IdType="pmc">PMC2891868</ArticleId><ArticleId IdType="pubmed">20063186</ArticleId></ArticleIdList></Reference><Reference><Citation>Freire E. A., Maia I. O., Nepomuceno J. C., Ciconelli R. M. Damage index assessment and quality of life in systemic lupus erythematosus patients (with long-term disease) in Northeastern Brazil. Clinical Rheumatology . 2007;26(3):423&#x2013;428. doi: 10.1007/s10067-006-0517-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10067-006-0517-6</ArticleId><ArticleId IdType="pubmed">17216369</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xf3;pez P., Mozo L., Guti&#xe9;rrez C., Su&#xe1;rez A. Epidemiology of systemic lupus erythematosus in a northern Spanish population: gender and age influence on immunological features. Lupus . 2003;12(11):860&#x2013;865. doi: 10.1191/0961203303lu469xx.</Citation><ArticleIdList><ArticleId IdType="doi">10.1191/0961203303lu469xx</ArticleId><ArticleId IdType="pubmed">14667105</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghodke-Puranik Y., Niewold T. B. Immunogenetics of systemic lupus erythematosus: a comprehensive review. Journal of Autoimmunity . 2015;64:125&#x2013;136. doi: 10.1016/j.jaut.2015.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2015.08.004</ArticleId><ArticleId IdType="pmc">PMC4628859</ArticleId><ArticleId IdType="pubmed">26324017</ArticleId></ArticleIdList></Reference><Reference><Citation>Arango M. T., Perricone C., Kivity S., et al. HLA-DRB1 the notorious gene in the mosaic of autoimmunity. Immunologic Research . 2017;65(1):82&#x2013;98. doi: 10.1007/s12026-016-8817-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-016-8817-7</ArticleId><ArticleId IdType="pubmed">27435705</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui Y., Sheng Y., Zhang X. Genetic susceptibility to SLE: recent progress from GWAS. Journal of Autoimmunity . 2013;41:25&#x2013;33. doi: 10.1016/j.jaut.2013.01.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaut.2013.01.008</ArticleId><ArticleId IdType="pubmed">23395425</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. S., Chung Y. H., Kim T. G., et al. Independent association of HLA-DR and FCgamma receptor polymorphisms in Korean patients with systemic lupus erythematosus. Rheumatology . 2003;42(12):1501&#x2013;1507. doi: 10.1093/rheumatology/keg404.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keg404</ArticleId><ArticleId IdType="pubmed">12867584</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim H. Y., Lee S. H., Yang H. I., et al. TNFB gene polymorphism in patients with systemic lupus erythematosus in Korean. The Korean Journal of Internal Medicine . 1995;10(2):130&#x2013;136. doi: 10.3904/kjim.1995.10.2.130.</Citation><ArticleIdList><ArticleId IdType="doi">10.3904/kjim.1995.10.2.130</ArticleId><ArticleId IdType="pmc">PMC4532044</ArticleId><ArticleId IdType="pubmed">7495771</ArticleId></ArticleIdList></Reference><Reference><Citation>Hachiya Y., Kawasaki A., Oka S., et al. Association of HLA-G 3&#x2032; untranslated region polymorphisms with systemic lupus erythematosus in a Japanese population: a case-control association study. PLoS One . 2016;11(6, article e0158065) doi: 10.1371/journal.pone.0158065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0158065</ArticleId><ArticleId IdType="pmc">PMC4917238</ArticleId><ArticleId IdType="pubmed">27331404</ArticleId></ArticleIdList></Reference><Reference><Citation>Hern&#xe1;ndez-Do&#xf1;o S., Jakez-Ocampo J., M&#xe1;rquez-Garc&#xed;a J. E., et al. Heterogeneity of genetic admixture determines SLE susceptibility in Mexican. Frontiers in Genetics . 2021;12, article 701373 doi: 10.3389/fgene.2021.701373.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fgene.2021.701373</ArticleId><ArticleId IdType="pmc">PMC8369992</ArticleId><ArticleId IdType="pubmed">34413879</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee H. S., Bae S. C. What can we learn from genetic studies of systemic lupus erythematosus? Implications of genetic heterogeneity among populations in SLE. Lupus . 2010;19(12):1452&#x2013;1459. doi: 10.1177/0961203310370350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/0961203310370350</ArticleId><ArticleId IdType="pubmed">20947557</ArticleId></ArticleIdList></Reference><Reference><Citation>Fernando M. M., Stevens C. R., Walsh E. C., et al. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS Genetics . 2008;4(4, article e1000024) doi: 10.1371/journal.pgen.1000024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pgen.1000024</ArticleId><ArticleId IdType="pmc">PMC2291482</ArticleId><ArticleId IdType="pubmed">18437207</ArticleId></ArticleIdList></Reference><Reference><Citation>L&#xfc;hder F., Katz J., Benoist C., Mathis D. Major histocompatibility complex class II molecules can protect from diabetes by positively selecting T cells with additional specificities. The Journal of Experimental Medicine . 1998;187(3):379&#x2013;387. doi: 10.1084/jem.187.3.379.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.187.3.379</ArticleId><ArticleId IdType="pmc">PMC2212118</ArticleId><ArticleId IdType="pubmed">9449718</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsai S., Santamaria P. MHC class II polymorphisms, autoreactive&#x2009;T-cells, and autoimmunity. Frontiers in Immunology . 2013;4:p. 321. doi: 10.3389/fimmu.2013.00321.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2013.00321</ArticleId><ArticleId IdType="pmc">PMC3794362</ArticleId><ArticleId IdType="pubmed">24133494</ArticleId></ArticleIdList></Reference><Reference><Citation>Rasouli-Saravani A., Tahamoli-Roudsari A., Basiri Z., et al. Relevance of autoantibody profile with HLA-DRB1 and -DQB1 alleles in a group of Iranian systemic lupus erythematosus patients. Immunology Letters . 2021;237:11&#x2013;16. doi: 10.1016/j.imlet.2021.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2021.06.004</ArticleId><ArticleId IdType="pubmed">34186156</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim K., Bang S. Y., Lee H. S., et al. The HLA-DR&#x3b2;1 amino acid positions 11-13-26 explain the majority of SLE-MHC associations. Nature Communications . 2014;5(1):p. 5902. doi: 10.1038/ncomms6902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms6902</ArticleId><ArticleId IdType="pubmed">25533202</ArticleId></ArticleIdList></Reference><Reference><Citation>Tkachenko O., Lapin S., Maslyansky A., et al. Influence of HLA-DRB1 susceptibility alleles on the autoantibodies spectrum of systemic lupus erythematosus in European part of Russia. Autoimmunity Reviews . 2019;18(5):558&#x2013;560. doi: 10.1016/j.autrev.2019.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.03.013</ArticleId><ArticleId IdType="pubmed">30844554</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>